"Not So Different": Strategies for Biosimilar Developers in a Litigious US Landscape
In August of this year, the US District Court for the District of New Jersey ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi. As a result of that decision, biosimilar etanercept appears to be on a lengthy hold in the US market, and that has a number of biosimilar stakeholders concerned. This week on the podcast, we’re speaking with Rick Lozano, vice president of Biosimilars and Integrated Business Development for AmerisourceBergen. We discuss the ruling in the case, its potential impacts on the healthcare system, and what drug makers can do now to help educate other stakeholders about biosimilars and improve uptake.
For the full episode, check out The Center for Biosimilars.